Jefferies Group LLC reaffirmed their buy rating on shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) in a report published on Friday, October 6th. Jefferies Group LLC currently has a $44.00 price objective on the stock.
RETA has been the topic of several other reports. Leerink Swann started coverage on shares of Reata Pharmaceuticals in a research report on Wednesday, September 13th. They set an outperform rating and a $43.00 target price on the stock. ValuEngine lowered shares of Reata Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, September 11th. Citigroup Inc. reiterated a buy rating and issued a $87.00 price objective (up from $39.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Stifel Nicolaus reiterated a buy rating and issued a $50.00 price objective (up from $38.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Finally, Robert W. Baird reiterated a buy rating and issued a $47.00 price objective on shares of Reata Pharmaceuticals in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $54.71.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) opened at 32.95 on Friday. The company’s market capitalization is $860.09 million. Reata Pharmaceuticals has a 12 month low of $18.51 and a 12 month high of $41.60. The stock’s 50 day moving average is $30.56 and its 200 day moving average is $27.58.
COPYRIGHT VIOLATION WARNING: “Reata Pharmaceuticals’ (RETA) Buy Rating Reiterated at Jefferies Group LLC” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/reata-pharmaceuticals-reta-buy-rating-reiterated-at-jefferies-group-llc/1700835.html.
In other Reata Pharmaceuticals news, Director James Edward Bass bought 8,064 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average price of $31.00 per share, with a total value of $249,984.00. Following the transaction, the director now owns 67,411 shares in the company, valued at $2,089,741. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 62.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RETA. Teachers Advisors LLC boosted its holdings in Reata Pharmaceuticals by 12.8% in the 4th quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock worth $221,000 after acquiring an additional 1,148 shares during the period. Bank of New York Mellon Corp boosted its holdings in Reata Pharmaceuticals by 18.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,213 shares of the company’s stock worth $503,000 after acquiring an additional 3,407 shares during the period. Victory Capital Management Inc. purchased a new position in Reata Pharmaceuticals in the 1st quarter worth approximately $483,000. FMR LLC boosted its holdings in Reata Pharmaceuticals by 40.6% in the 1st quarter. FMR LLC now owns 237,606 shares of the company’s stock worth $5,382,000 after acquiring an additional 68,600 shares during the period. Finally, Fifth Third Bancorp purchased a new position in Reata Pharmaceuticals in the 1st quarter worth approximately $395,000. Hedge funds and other institutional investors own 15.56% of the company’s stock.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.